Analysis of Key Market Segments Influencing the Genomic Cancer Panel and Profiling Market

The genomic cancer panel and profiling market is set for significant expansion as advances in technology and growing healthcare demands continue to reshape oncology diagnostics. This sector is rapidly evolving, driven by innovative testing methods and increasing integration of genomic data to personalize cancer treatment. Below, we explore the market's size projections, key players, emerging trends, and segmentation details.

Expected Market Size and Growth Forecast for the Genomic Cancer Panel and Profiling Market
The market for genomic cancer panels and profiling is anticipated to reach $15.45 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4%. This upward trajectory is fueled by the broadening use of companion diagnostics, increasing adoption of liquid biopsy techniques, the integration of artificial intelligence into genomic analyses, the expansion of oncology screening programs, and the development of more affordable sequencing platforms. Important trends shaping the market include the rising use of multi-gene cancer panels, enhanced next-generation sequencing applications, growth in liquid biopsy testing, demand for personalized oncology solutions, and greater utilization of genomic data in clinical decision-making processes.

Download a free sample of the genomic cancer panel and profiling market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24225&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Market Players Driving the Genomic Cancer Panel and Profiling Industry
Key organizations dominating the genomic cancer panel and profiling market include Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., and Predictive Oncology Inc.

In a strategic move to enhance its capabilities in liquid biopsy and cancer detection, Quest Diagnostics, a US clinical laboratory company, acquired Haystack Oncology in June 2023 for an undisclosed sum. Haystack Oncology specializes in developing cutting-edge liquid biopsy technologies aimed at early cancer detection and ongoing monitoring, which has strengthened Quest Diagnostics' genomic testing portfolio.

View the full genomic cancer panel and profiling market report:
https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Technological Innovations Shaping the Genomic Cancer Panel and Profiling Market
Companies in this industry are heavily investing in next-generation sequencing (NGS) technologies to boost the precision, speed, and comprehensiveness of cancer diagnostics. NGS allows for high-throughput, detailed genetic analysis that can detect mutations and other genomic features critical to personalized treatment planning. For example, in April 2025, QIAGEN N.V., a biotechnology firm based in the Netherlands, introduced QIAseq panels designed for use with next-generation sequencers. These panels cover over 700 genes and target both clinical and research applications, aiming to improve cancer diagnostic accuracy and therapeutic approaches.

Market Segmentation of the Genomic Cancer Panel and Profiling Industry
The genomic cancer panel and profiling market is divided into several key segments:
1) Tissue Testing: Solid Tissue Testing and Liquid Tissue Testing
2) Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), and other technologies
3) Cancer Panel Types: Single-Gene Panels and Multi-Gene Panels
4) Application Areas: Clinical and Research
5) End Users: Hospitals, Research and Academic Institutes, Clinical and Diagnostic Laboratories, and other end users

Detailed subcategories include:
- Solid Tissue Testing: biopsy samples, surgical resection samples, formalin-fixed paraffin-embedded (FFPE) tissues, and fresh frozen tissues
- Liquid Tissue Testing: blood, urine, saliva, cerebrospinal fluid (CSF), and other bodily fluids

This comprehensive segmentation provides a thorough understanding of the genomic cancer panel and profiling market's structure and its diverse areas of application.

Our 2026 reports feature deeper market intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.